Health Care • Biotechnology: Pharmaceutical Preparations
$30.52 ▲ +0.57
(+1.90%)
MKT CAP: $170.71B • VOL: 45.49M
52W L $24 52W H $31
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$26
MEDIAN
$34
MEAN
$35
HIGH
$42
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PFE TAPE
PFE // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $36.93 | $35.10 | 2025-02-14 | $27.77 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $38.46 | $36.01 | 2025-02-06 | $28.69 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $34.79 | $33.57 | 2025-01-29 | $29.30 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $31.13 | — | 2025-01-17 | $29.91 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $26.86 | $28.99 | 2025-01-09 | $27.16 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $36.32 | $31.74 | 2024-12-18 | $26.55 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $29.60 | $30.83 | 2024-12-04 | $28.38 | -4.3% | 48% | C |